Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Yiqi Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4261-6888; OpenAlex author ID A5100605283, A5133192983. Sources: OpenAlex.

Their work

Papers
17 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 3 papers · 2014: 4 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 17

  1. Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1. Co-author DOI 10.1371/journal.pone.0345697↗
  2. Pancreatic cancer: challenges and opportunities. Co-author DOI 10.1186/s12916-018-1215-3↗
  3. STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α. Co-author DOI 10.1158/0008-5472.can-17-0067↗
  4. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. First author DOI 10.1080/15384101.2015.1127471↗
  5. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.04.048↗
  6. Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications. Co-author DOI 10.1155/2014/386561↗
  7. Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1159/000365306↗
  8. Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. First author DOI 10.3892/mco.2014.271↗
  9. Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Co-author DOI 10.1089/cbr.2012.1389↗
  10. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. First author DOI 10.1097/mpa.0b013e3182962acb↗
  11. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-12-3630↗
  12. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Co-author DOI 10.1002/ijc.26422↗
  13. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗
  14. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. First author DOI 10.1007/s10620-010-1285-3↗
  15. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Co-author DOI 10.1007/s11033-010-0632-y↗
  16. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. Co-author DOI 10.1038/ajg.2011.281↗
  17. Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage. Co-author DOI 10.4161/jig.1.1.14596↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiangyu Kong · 8 shared papers, 2011–2017 · strength 0.35
  2. Wenbo Zhu · 1 shared paper, 2026 · strength 0.29
  3. Lei Li · 1 shared paper, 2026 · strength 0.29
  4. Xiangyu Kong · 1 shared paper, 2026 · strength 0.29
  5. Jun Gao · 8 shared papers, 2011–2016 · strength 0.29
  6. Yan-fang Gong · 6 shared papers, 2011–2016 · strength 0.20
  7. Zhao‐Shen Li · 4 shared papers, 2012–2017 · strength 0.19
  8. Zhaoshen Li · 5 shared papers, 2011–2014 · strength 0.19
  9. Zhaoshen Li · 4 shared papers, 2011–2014 · strength 0.17
  10. Keping Xie · 3 shared papers, 2013–2017 · strength 0.14
  11. Fanyang Kong · 2 shared papers, 2014–2017 · strength 0.12
  12. Min Li · 1 shared paper, 2018 · strength 0.12
  13. Huiyun Zhu · 1 shared paper, 2018 · strength 0.12
  14. Tuo Li · 1 shared paper, 2018 · strength 0.12
  15. Tao Sun · 2 shared papers, 2014 · strength 0.12
  16. Dacheng Xie · 2 shared papers, 2014–2017 · strength 0.10
  17. Minghao Liu · 2 shared papers, 2013 · strength 0.09
  18. Jiujie Cui · 2 shared papers, 2013–2014 · strength 0.08
  19. Zhendong Jin · 2 shared papers, 2011 · strength 0.07
  20. Jianqiang Liu · 2 shared papers, 2012–2013 · strength 0.07
  21. Lei Li · 1 shared paper, 2017 · strength 0.06
  22. Jiawei Du · 1 shared paper, 2017 · strength 0.06
  23. Xiaowei Wang · 2 shared papers, 2011–2012 · strength 0.05
  24. Xiaoyan Ning · 1 shared paper, 2016 · strength 0.05
  25. Hongyu Wu · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.